@article {MAEDA3825, author = {CHIE MAEDA and AKIRA IIZUKA and HARUO MIYATA and RYOTA KONDOU and TADASHI ASHIZAWA and AKARI KANEMATSU and KYOKO WATANABE and SHOICHI DEGUCHI and KOICHI MITSUYA and NAKAMASA HAYASHI and YOSHIAKI ABE and KEN YAMAGUCHI and YASUTO AKIYAMA}, title = {Alternative Evaluation of an ELISPOT Assay Using Cytokine Activity as a Novel Parameter}, volume = {41}, number = {8}, pages = {3825--3831}, year = {2021}, doi = {10.21873/anticanres.15175}, publisher = {International Institute of Anticancer Research}, abstract = {Background/Aim: The enzyme-linked immunospot (ELISPOT) assay is a well-established method used to evaluate the strength of T cell-mediated immune activity, and accepted as a standard functional immunological assay. Cytokine activity is a novel parameter reflecting spot size and intensity, which has not been used in ELISPOT assay before. Materials and Methods: In the present study, from 113 ELISPOT assay data derived from previous clinical trials with dendritic cell vaccines, both spot number count and cytokine activity data for IFN-γ secretion were obtained using an ELISPOT reader. Comparing the new parameter cytokine activity with the existing parameter spot number, the feasibility of cytokine activity was investigated. Results: There were no significant differences in sensitivity and specificity between spot number and cytokine activity among ELISPOT assay data from CMVpp65 and other antigen peptide-stimulated cytotoxic T lymphocytes. Conclusion: Although cytokine activity is a novel parameter unreported so far, it did not show any advantages in the evaluation T cell immune responses compared to the existing spot number parameter.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/41/8/3825}, eprint = {https://ar.iiarjournals.org/content/41/8/3825.full.pdf}, journal = {Anticancer Research} }